SubHero Banner

Xarelto® (rivaroxaban) – Expanded indication

October 30, 2017 – Janssen Pharmaceuticals announced the FDA approval of Xarelto (rivaroxaban) 10 mg for the reduction in the risk of recurrence of deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months.

Download PDF